title: Organobismuth compounds: activity against Helicobacter pylori.
abstract: METHODS
  The antibacterial activity of originally devised and synthesized organobismuth compounds was tested against fresh clinical isolates of Helicobacter pylori and compared with clinically well-established inorganic bismuth salts currently used in triple antibacterial treatment to eradicate H. pylori. The test conditions in vitro were standard for determination of minimum inhibitory concentrations (MICs).
  
  
  RESULTS
  Organic compounds with covalently bound bismuth showed stronger and more consistent antibacterial activity than inorganic bismuth salts. Whereas the most active among the standard therapeutic inorganic compounds showed MICs against the test organisms of 4-8 mg/l (bismuth salicylate) and 0.5-64 mg/l, the most active neosynthesized organic substance, tris(2.6-dimethylphenyl)-bismuthine, consistently showed an MIC of 4 mg/l against all bacterial strains.
  
  
  CONCLUSIONS
  The new line of organobismuth compounds might offer a therapeutic potential against the bacteria causing peptic ulcer disease.
authors: Dept. of Medicinal Chemistry, School of Pharmacy, University of Oslo, Norway.
authors: A
authors: A
authors: Dahlgren
authors: C
authors: C
authors: Gløgård
authors: M
authors: M
authors: Gammelsaether
authors: A J
authors: AJ
authors: Aasen
authors: J
authors: J
authors: Klaveness
authors: B P
authors: BP
authors: Berdal
authors: T
authors: T
authors: Bergan
mesh_terms: D001729:Bismuth / Q000494:pharmacology*; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D007287:Inorganic Chemicals; D008826:Microbial Sensitivity Tests; D009930:Organic Chemicals; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology
chemical_list: D007287:Inorganic Chemicals; D009930:Organic Chemicals; D001729:Bismuth